{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:49:11Z","timestamp":1789224551706,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 DK118120"],"award-info":[{"award-number":["K08 DK118120"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1053\/j.ajkd.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T12:12:47Z","timestamp":1623240767000},"page":"120-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Capmatinib-Induced Pseudo\u2013Acute Kidney Injury: A Case Report"],"prefix":"10.1053","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-2274","authenticated-orcid":false,"given":"Arjunmohan","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ajkd.2021.04.009_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3747\/co.24.3496","article-title":"Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations","volume":"24","author":"Hsu","year":"2017","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.009_bib2","doi-asserted-by":"crossref","first-page":"35770","DOI":"10.1038\/srep35770","article-title":"The efficacy and risk profile of c-Met inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Ye","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2021.04.009_bib3","first-page":"763","article-title":"Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignore","volume":"12","author":"Camidge","year":"2014","journal-title":"Clin Adv Hematol Oncol HO"},{"issue":"8","key":"10.1053\/j.ajkd.2021.04.009_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","article-title":"Capmatinib for the treatment of non-small cell lung cancer","volume":"19","author":"Vansteenkiste","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1053\/j.ajkd.2021.04.009_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.annonc.2020.03.293","article-title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","volume":"31","author":"Schuler","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1053\/j.ajkd.2021.04.009_bib6","doi-asserted-by":"crossref","first-page":"viii741","DOI":"10.1093\/annonc\/mdy424.090","article-title":"Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET\u0394ex14 mutated advanced non-small cell lung cancer (NSCLC)","volume":"29","author":"Wolf","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1053\/j.ajkd.2021.04.009_bib7","article-title":"Adverse drug reaction probability Scale (Naranjo) in drug induced liver injury","year":"2012"},{"issue":"5","key":"10.1053\/j.ajkd.2021.04.009_bib9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10637-016-0379-y","article-title":"The renal effects of ALK inhibitors","volume":"34","author":"Izzedine","year":"2016","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.009_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226509","article-title":"Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study","volume":"15","author":"Willey","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1053\/j.ajkd.2021.04.009_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.ki.5002042","article-title":"Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study","volume":"71","author":"Keller","year":"2007","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2021.04.009_bib12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated or MET-amplified non\u2013small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.009_bib13","first-page":"49","article-title":"Crizotinib: renal safety evaluation","volume":"1","author":"Perazella","year":"2017","journal-title":"J\u00a0Onco-Nephrol"},{"key":"10.1053\/j.ajkd.2021.04.009_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.05.011","article-title":"Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis","volume":"133","author":"Awad","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1053\/j.ajkd.2021.04.009_bib15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.28478","article-title":"Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib","volume":"120","author":"Brosnan","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.ajkd.2021.04.009_bib16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ekir.2017.02.008","article-title":"Anticancer drug-induced acute kidney injury","volume":"2","author":"Izzedine","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2021.04.009_bib17","doi-asserted-by":"crossref","first-page":"omy009","DOI":"10.1093\/omcr\/omy009","article-title":"Progressive renal insufficiency related to ALK inhibitor, alectinib","volume":"2018","author":"Nagai","year":"2018","journal-title":"Oxf Med Case Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.009_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13256-018-1849-y","article-title":"Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature","volume":"12","author":"Ramachandran","year":"2018","journal-title":"J\u00a0Med Case Reports"},{"issue":"2","key":"10.1053\/j.ajkd.2021.04.009_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.ajkd.2021.04.009_bib20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2017.09.011","article-title":"Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours","volume":"86","author":"Sch\u00f6ffski","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.009_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/nep.13086","article-title":"Cabozantinib-induced renal thrombotic microangiopathy","volume":"23","author":"Manna","year":"2018","journal-title":"Nephrology"},{"issue":"10072","key":"10.1053\/j.ajkd.2021.04.009_bib23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.ajkd.2021.04.009_bib24","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non\u2013small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2021.04.009_bib26","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621006405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621006405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:40:26Z","timestamp":1759462826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638621006405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0272638621006405"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.009","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capmatinib-Induced Pseudo\u2013Acute Kidney Injury: A Case Report","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}